Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2013

View Archived Issues

VaxLogic licenses QS-21 adjuvant from Agenus

Scientists create zebrafish model of hyperammonemia

Endece Neural receives funding to advance myelin repair compound

Inotek Pharmaceuticals raises funds to support development of trabodenoson

Novel genetic susceptibility loci identified in patients with anorexia nervosa

Eteplirsen shows continued stability on walking test in DMD study

Phase II clinical comparison of drug delivery systems in patients with type 2 diabetes

Etubics receives SBIR grant for breast cancer immunotherapeutic

Evotec achieves another milestone in collaboration with Boehringer Ingelheim

Kissei and JCR Pharmaceuticals collaborate on darbepoetin alfa biosimilar

[68Ga]Pentixafor allows PET imaging of CXCR4 expression in humans

Results of phase III trial demonstrate improvements in PFS and PSA responses with ipilimumab

FDA grants orphan drug designation to OMS-824 for Huntington's disease

Gliknik enters agreement with Pfizer for autoimmune disease drug candidate

AcelRx Pharmaceuticals submits Zalviso NDA

Lithera reports data from the phase IIb RESET trial for LIPO-202

Astellas Pharma reports topline phase III data for isavuconazole

FDA approves Cimzia for treatment of active psoriatic arthritis

New furin inhibitors disclosed by U.S. researchers

Glucox Biotech patents novel NADPH oxidase inhibitors

Stapled TRF2 peptides allow exploration of RAP1-TRF2 interaction

Bracco Imaging presents new agents for magnetic resonance imaging

Lupin discloses novel MEK/ERK inhibitors

FDA grants orphan drug status to several drugs for cancer treatment

FDA approves vortioxetine for major depressive disorder

Vertex files sNDA for Kalydeco

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...